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High-risk human papillomaviruses (HR-HPV) are the necessary cause of cervical carcinomas and there is an increasing interest in using
HR-HPV DNA detection in adjunction to cytological examination for primary cervical screening. To determine whether women with
a normal smear negative for HR-HPV DNA detection with the Hybrid Capture II assay might represent a low-risk population for
developing a high-grade squamous intraepithelial lesion (HSIL), 4401 women have been followed in a period of 12–72 months
(median¼34 months). During this follow-up, four HSIL and one microinvasive carcinoma have been detected in this cohort (three in
the cohort of 3526 women 429 years). The global negative predictive value (NPV) of double-negative tests is thus of 99.9% (ninety-
five percent confidence interval (95% CI): 99.8–100%), whereas cytology alone gives an NPV of 99.2% (95% CI: 98.9–99.5%). If we
obtain a second negative HR-HPV test 1–2 years after the initial test, the NPV is 100%. The NPV is also of 100% in the cohort of
women 449 years. We conclude that all these women could be safely screened at longer intervals between 3 and 5 years. This
policy will offset the increased costs induced by an additional HR-HPV testing in primary screening.
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It is now well established that oncogenic (high-risk) human
papillomaviruses (HPV) are a necessary causal factor in the
development of cervical intraepithelial and invasive neoplasias
(Lorincz et al, 1992; Bosch et al, 1995; Walboomers et al, 1999; Zur
Hausen, 2002). Infections with high-risk HPV (HR-HPV) are
associated with a relative risk of between 8 and 11 for the
development of squamous intraepithelial lesions (SIL) (Gaarenst-
room et al, 1994). Moreover, only low-grade SIL (LSIL) containing
HR-HPV progress to high-grade SIL (HSIL) (Koutsky et al, 1992).
Owing to this, there is an increasing interest in using HPV DNA
detection either alone or in addition to classic cytological
examination for primary cervical screening (Cuzick et al, 1995,
1999, 2003; Meijer et al, 1998; Clavel et al, 1999, 2001; Kuhn et al,
2000; Ratnam et al, 2000; Schiffman et al, 2000; Schneider et al
2000; Kjaer et al, 2002; Petry et al, 2003; Lorincz and Richart, 2003;
Sherman et al, 2003). Most authors consider that a positive HPV
testing selects a population at high risk for developing an HSIL,
while a negative HPV testing has a very good negative predictive
value (NPV). Indeed, considering that the mean time from
detectable LSIL to preclinical invasive cancer is 12–13 years
(Gustafson and Adami, 1989), Meijer et al (1998) have proposed
that women with cytologically normal smears and a negative HR-
HPV test could be rescreened every 8 years.
Hybrid Capture-II (HC-II), a commercial HPV detection test,
(Digene, Gaithersburg, MD, USA) was introduced 7 years ago
(Lorincz, 1996). Hybrid Capture-II is a nonradioactive, reproducible,
relatively rapid, liquid hybridisation assay in microtiters designed to
detect 18 HPV types divided into high-risk (types 16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59 and 68) and low-risk (types 6, 11, 42, 43 and
44) groups. The sensitivity of this assay is quite similar to that of
polymerase chain reaction (PCR) (Peyton et al, 1998). Recently, the
Food and Drug Administration in the USA has authorised the use of
this assay in women aged 30 years and older for primary screening
in adjunction to cytology. In a recent preliminary study, using this
test in women with normal smears, we have shown that recurrent
infection detected with HC-II was associated with a relative risk of
incident HSIL of 237.3 when HR-HPV test remained positive at two
controls. In contrast, in the cohort of 2432 women testing negative
for HR-HPV infection followed on a period of 60 months, only two
women developed an HSIL (Bory et al,2 0 0 2 ) .T h u st h eN P Vo fa
negative test with HC-II could be useful in primary screening when
associated with a smear within normal limits.
At the present time, there are few longitudinal studies with a
detailed and prolonged follow-up of women with a normal smear
with a negative HR-HPV testing (Kjaer et al, 2002; Sherman et al,
2003). Thus, the aim of the present study is to evaluate on a large
population of women with an initial smear within normal limits
the usefulness and limitations of a negative HR-HPV testing in
such women. For that, we have followed on a period from 12 to 72
months 4401 women with a normal smear and a negative HR-HPV
testing at enrolment. The end point in all these women was the
detection of an HSIL at the histological examination.
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yMATERIAL AND METHODS
Study population
A total of 4401 women with a median age of 41 years (range 15–79
years) were recruited for the study between August 1997 and
November 2002. This population was restricted to women who
underwent their routine screening in the Department of Obstetrics
and Gynaecology of the CHU of REIMS. We excluded subjects on
the basis of a recent cytological abnormality and/or an untreated
cervical lesion in the past 2 years and patients with AIDS. All
women were informed of the aim of the study and gave their
consent. The follow-up of these women was between 12 and 72
months (median¼34 months).
Cytologic diagnosis
At the first gynaecologic examination, in 1278 women, two samples
were taken: first, a cytological smear with an Ayre’s spatula, for
classical cytology, then one scrape for the HC-II test with a
Cervexbrush (Medscan, Uppsala, Sweden). These samples were
suspended in 1ml of specimen transport medium for HPV testing
(Digene, Gaithersburg, MD, USA). In another group, 3123 women
had only one cervical scrape with a Cervexbrush at the first entry.
Samples were prepared for liquid-based cytology with the
ThinPrep technique (Cytyc Corporation, Marlborough, MA,
USA) and 4ml of the sample were used for HPV testing. In total,
considering the first samples and the follow-up of women, we
collected 10641 cervical smears and scrapes, including 9112 liquid-
based samples. Smears were classified according to the Bethesda
system for reporting cervical or vaginal cytological diagnosis. We
selected women with adequate smears including metaplastic and/
or endocervical cells according to the criteria of Bethesda, which
represented 93% of our total smears. However, even if the smear
was not considered as adequate, we also included women with
smears with cytological abnormalities. The cytotechnicians and
pathologists involved in the study were not informed about the
results of the HPV testing. All smears showing cytological
abnormalities and biopsy specimens were examined by the same
two independent pathologists, without knowledge of cytology
results for the biopsies examination. The results were compared
and if the first two diagnoses disagreed, a third pathologist
reviewed the case with no knowledge of preceding diagnoses.
Consensus diagnoses were determined by two-thirds majority
when possible and remaining discrepancies resolved by conference
review. Patients with HSIL were systematically treated by loop
electrosurgical excision procedure (LEEP). Data from these LEEP
specimens were included in the disease definitions.
Colposcopic referral
In our protocol (Figure 1), all the women presenting in their
follow-up cytological abnormalities (from ASCUS to HSIL) were
systematically recalled for colposcopy in the next few weeks, at an
interval ranging from 14 to 160 days (mean 95 days) after entry
examination. Punch biopsy specimens were taken from the areas
colposcopically suspicious for cervical intraepithelial neoplasia
(CIN). All the women with smears within normal limits but
presenting an HR-HPV infection were also systematically recalled
6–12 months later for a new cytological examination and HR-HPV
testing followed by colposcopy if a lesion and/or a persistent HR-
HPV infection was detected. Punch biopsy specimens were taken
from the areas colposcopically suspicious for CIN. The women
with a second HR-HPV test positive without any detectable lesions
were recalled 6–12 months later for a third control with cytological
examination and HR-HPV testing and the same indications as
above for colposcopy and biopsy. In the present study, 455 women
with initial normal smears and without any HR-HPV infection had
also randomly a colposcopic examination. There were not
particular selection criteria for colposcopy. The primary end point
of our study was the detection of a histologically proven HSIL at
the biopsy and/or on the LEEP specimen.
HPV testing
When conventional cytology was performed, specimens for HPV
DNA testing were suspended in 1ml of ViraPap/Viratype transport
medium (Digene, Gaithersburg, MD, USA) and stored at  201C
until further processing. When samples were used for liquid-based
cytology, 4ml of the sample were centrifuged and the cell pellet
was resuspended in 200ml of phosphate-buffered saline for HPV
testing. Human papillomavirus DNA detection was performed by
the commercially available HC-II System (Digene). All scrapes
were analysed for the presence of HR-HPV types 16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59 and 68. This enzyme-linked immunosor-
bent assay is based on a sandwich hybridisation followed by a
nonradioactive alkaline phosphatase reaction with chemolumines-
cence in microplates. The chosen positive threshold of this test was
1.0pgml
 1 of HPV DNA.
Samples were classified as positive for HR-HPV DNA if the
relative light unit (RLU) reading obtained from the luminometer
was equal or greater than the mean of the three positive control
values supplied by the HC-II kit. As some authors have reported
that increasing HPV DNA levels of HR-HPV types were the
principal predictors of CIN (Cox et al, 1995), we used, as proposed,
the ratio RLU/positive controls values to quantify HR-HPV DNA
in our samples. Moreover, we added other positive controls such as
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Figure 1 Protocol of follow-up of women with normal cytology and a
negative HR-HPV testing.
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the reproducibility of the HC-II sensitivity.
Statistical methods
The statistical methods used were mostly descriptive. Positive
predictive value (PPV) and NPV were determined by comparing
the results of each test to the gold standard of histology. A few
HSIL may have been missed if they were negative on both tests,
and thus women were not referred for colposcopy. Using either
binomial or normal distribution, 95% percent confidence interval
(95% CI) for these values were assessed according to the data.
Overall occurrence of HSIL and carcinoma was assessed by
Kaplan–Meier analysis with the Mantel Cox’s log-rank score for
determining statistical significance. Moreover, differences between
HR-HPV detection and cytological diagnosis values were com-
pared using Fisher’s exact test or w
2 statistics as adequate, with a P-
value set to 5%.
RESULTS
The results are summarised in Tables 1–3. In our series, 4019
women (3242 women 429 years; 1080 women 449 years) had two
consecutive normal smears without any HR-HPV infection
detected within 12–70 months (median¼32 months). In total,
2953 women had only two smears (2392 women 429 years; 840
women 449 years). Of these, 956 women (768 women 429 years;
220 women 449 years) had three or more normal smears without
any HR-HPV infection. In all, 110 women (82 women 429 years;
20 women 449 years) after two normal smears without HR-HPV
infection presented an HR-HPV infection and/or cytological
abnormalities (ASCUS and LSIL). No HSIL was detected in the
follow-up of all these women. Moreover, the colposcopic
examination of 455 women with persistent normal smears without
any HR-HPV infection performed 24–71 months after enrolment
(median¼37 months) failed to detect histological lesions, even in
the eight cases evocative of viral infection by colposcopy.
In total, 382 women (284 women 429 years; 92 women 449
years) developed an HR-HPV infection and/or cytological
abnormalities at the second control (median¼37 months). At
the present time, 136 had only two smears (97 women 429 years;
30 women 449 years). In two women (34 and 35 years old),
cytology-detected HSIL and an HR-HPV infection was present at
the second control, at 17 and 24 months, respectively. These
cytological HSIL corresponded at the histological examination to
one HSIL and one microinvasive carcinoma, discovered 17 months
after the first normal smear. According to our protocol of follow-
Table 3 Follow-up of women 449 years with initial normal smears HR-HPV negative (N )
Follow-up N /N  Three or more N  N /N /X N /X HG Number of women
12–23 months 197 4 0 8 0 209
24–35 months 417 32 2 52 0 503
36–47 months 198 87 7 23 0 315
48–59 months 21 49 9 8 0 87
60–72 months 7 48 2 1 0 58
840 (71.7%) 220 (18.8%) 20 (1.7%) 92 (7.8%) 0 1172
HR-HPV¼high-risk human papillomaviruses; HSIL¼high-grade squamous intraepithelial lesion. X corresponds to the apparition of cytological abnormalities (from ASCUS to
HSIL) and/or a positive HR-HPV testing. HG corresponds to histologically proven HSIL.
Table 2 Follow-up of women 429 years with initial normal smears HR-HPV negative (N )
Follow-up N /N  Three or more N  N /N /X N /X HG+ Number of women
12–23 months 557 15 2 38 1 612
24–35 months 1115 94 8 118 2 1335
36–47 months 557 226 30 87 0 900
48–59 months 94 182 27 26 0 329
60–72 months 69 251 15 15 0 350
2392 (67.8%) 768 (21.8%) 82 (2.3%) 284 (8.0%) 3 3526
HR-HPV¼high-risk human papillomaviruses; HSIL¼high-grade squamous intraepithelial lesion. X corresponds to the apparition of cytological abnormalities (from ASCUS to
HSIL) and/or a positive HPV testing. HG+ corresponds to the histologically proven two HSIL and one microinvasive carcinoma. These lesions have been detected only in the
N /X cohort.
Table 1 Follow-up of women with initial normal smears with negative HR-HPV testing (N )
Follow-up N /N  Three or more N  N /N /X N /X HG+ Number of women
12–23 months 750 19 2 54 1 825
24–35 months 1325 125 11 151 2 1612
36–47 months 662 285 42 120 2 1109
48–59 months 124 224 39 39 0 426
60–72 months 92 303 16 18 0 429
2953 (67.1%) 956 (21.7%) 110 (2.5%) 382 (8.7%) 5 4401
HR-HPV¼high-risk human papillomaviruses; HSIL¼high-grade squamous intraepithelial lesion. X corresponds to the apparition of cytological abnormalities (from ASCUS to
HSIL) and/or a positive HR-HPV testing. HG+ corresponds to the histologically proven four HSIL and one microinvasive carcinoma. These lesions have been detected only in the
N /X cohort.
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two HR-HPV-positive HSIL were diagnosed at the cytological and
histological examinations at a third control at 31 months in a 45-
year-old woman and at 38 months in a 25-year-old women. One
HR-HPV-positive HSIL was detected at a fourth control by
cytology and histology at 41 months in a 26-year-old woman.
In the total follow-up, cytological abnormalities were detected in
140 women (3.2%) of the total population, in 96 women 429 years
(2.7%) and in 27 women 449 years (2.3%). HR-HPV infection
occurred in the follow-up of 116 women o30 years (13.2%, with
63.3% of regression) and in 323 women 429 years (9.2%, with
70.4% of regression).
Thus, the global NPV for the development of an HSIL is 99.9%
(95% CI: 99.8–100%) in the general population, 99.9% (95% CI:
99.8–100%) in women 429 years and 100% in women 449 years.
If we consider the follow-up obtained on 45 years of 96 women
with two initial consecutive negative HR-HPV testing at 12–24
months of interval, the NPV for the development of an HSIL is
100% whatever the age of the women. In contrast, the PPV of a
positive HR-HPV test following an initial normal smear without
HR-HPV infection for the detection of an HSIL is 1.1% (95% CI:
0.1–2.1%).
For comparison, if we consider, in our total cohort of 4986
women (3931 women 429 years), attending routine screening with
normal smears whatever the HPV testing with a similar protocol of
follow-up on a period from 12 to 72 months, 34 HSIL were detected
(19 in women 429 years). Thus, for this cohort, the NPV of a
normal smear alone for the development of an HSIL is 99.3% (95%
CI: 99.2–99.4%) for the total population and 99.5% (95% CI: 99.4–
99.6%) for the women 429 years. Moreover, if we consider a
similar cohort of 5592 women without limitations of time in the
follow-up, we have detected at the present time 71 HSIL (46 HSIL
in 4321 women 429 years), which gives an NPV of 98.7% (95% CI:
98.5–98.9%) in the total population and an NPV of 98.9% (95% CI:
98.6–99.2%) in women 429 years. Indeed, 32 HSIL (24 HSIL in
women 429 years) have been discovered after an initial positive
HPV test before 12 months of follow-up.
The Kaplan–Meier curves comparing the occurrence of HSIL
and carcinoma in the total population (Figure 2), in women 429
years (Figure 3), also clearly demonstrate that there is a significant
difference (Po0.001) between the populations with initial smears
with HR-HPV-positive testing compared to populations with a
negative test.
DISCUSSION
This work is at the present time the only longitudinal study using
the HC-II assay in association with cervical smears for the follow-
up of women with both negative tests at enrolment. Indeed, in the
work of Kjaer et al (2002) on women o29 years, PCR testing for
the detection of HPV was performed on specimens collected into
phosphate-buffered saline, and the authors focused their study on
women with normal smears and HPV infection. In a related study,
the work of Sherman et al (2003) was conducted with HC-II assay
on cervicovaginal lavage specimens, a technique that is not as good
for sampling the endocervical canal as direct brushing. These
authors detected 48 HSIL (0.3%) in their 10 years follow-up of
17594 women with normal smears, but HPV testing results were
not used for any aspect of the clinical management or follow-up of
the women. Our present study represents a longitudinal experience
on 4401 women with different intervals and modalities of follow-
up. The protocol that we applied after the discovery of an HR-HPV
infection in women with normal smears clearly induces a bias
increasing the number of HSIL early detected and largely explains
the absence of detection of such lesions after 4 years of follow-up.
It is equally true that we cannot also exclude that some cervical
lesions, even HSIL, have spontaneously regressed during the mean
time of follow-up, especially when two consecutive controls were
distant 45 years. Moreover, we obtained long time follow-up 45
years data for 429 women and additional HSIL may be detected
with a more extensive study. However, at the present time, our
study gives a global NPV of 99.9% for the development of an HSIL
and carcinoma in women with an initial smear within normal
limits and a negative HR-HPV test result. The occurrence of
cytological abnormalities in 3.2% of our population is also lower
than the percentage of 5.3% of abnormal smears reported in the
literature in general primary screening (Stoler, 2000) (5.2% in our
own laboratory). Moreover, if we consider our own previous
results on women with normal smears and a positive HR-HPV test
with a follow-up, the PPV for detecting an HSIL is 7.7% for one test
and 21.2% for recurrent HR-HPV infection (Bory et al, 2002). This
PPV is only of 1.1% when a previous smear is normal without any
HR-HPV infection detected. Thus, the women with double-
negative tests really represent a low-risk population for the
development of HSIL.
In our series, we detected four HSIL and one microinvasive
carcinoma in the follow-up within 17–41 months after the initial
normal smear. These HSIL were all CIN3. They were all positive for
HR-HPV testing at the time of diagnosis. The initial smears were
reviewed. They were all adequate and the first cytological diagnosis
was confirmed. The viral load of the initial smear expressed
semiquantitatively by the HC-II was low and under the threshold
of 1.0pgml
 1 in all cases, and thus the negative HR-HPV test was
also confirmed. Despite decades of study, the natural history of
cervical intraepithelial lesions is still not completely understood.
Time (months)
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Figure 2 Kaplan–Meier analysis for the occurrence of an HSIL in the
whole population. Squares: women with initial negative HR-HPV testing.
Circles: women with initial positive HR-HPV testing. Po0.001.
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Figure 3 Kaplan–Meier analysis for the occurrence of an HSIL in the
population of women 429 years. Squares: women with initial negative HR-
HPV testing. Circles: women with initial positive HR-HPV testing. Po0.001.
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particularly the microinvasive carcinoma in our series, may
correspond to a rapid and direct transformation of the cervical
cells by integrated HR-HPV DNA, which may be initially
undetectable by the HC-II assay. Indeed, prospective studies
suggest that some HSIL can develop independently from low-grade
lesions. Koutsky et al (1992) found that most cases of HSIL arose
de novo in the absence of a cytologically detectable low-grade
lesion. In the same way, Nobbenhuis et al (1999) reported that 88%
of the incident cases of cervical intraepithelial lesions were first
identified as HSIL. Thus, the few HSIL observed in our series could
develop de novo at the squamoglandular epithelial junction of the
cervix with a particular rapid evolutive profile, and this may
explain that both initial cytology and HPV testing have no
predictive value in these cases.
In our study, we have not selected women according to their age
for the follow-up. The American Cancer Society (Saslow et al,2 0 0 2 )
and recently the American College of Obstetricians and Gynaecol-
ogists have recommended in their guidelines adjunctive HPV testing
in women aged 30 years or older for primary screening. They
consider that transient HPV infections are common in women
younger than 30 years and a positive test result may lead to
unnecessary additional evaluation and treatment. However, in our
series, if the prevalence of HR-HPV infections in the follow-up is
significantly higher in women o30 years (13.2 vs 9.2% in women of
30 years and older, Po0.001), at the present time, the percentage of
transient infection is identical in these two populations (63.3% in
women o30 years vs 70.4% in women of 30 years and older).
Moreover, we have to emphasise that two out of the five lesions
detected in our general population were in 25- and 26-year-old
women. Thus, in our experience, the NPV is not different in women
429 years compared to the general population. In another way, if
we consider the low prevalence of HSIL in women 450 years
attending a regular screening until this age, a double-negative test
with an NPV of 100% in this cohort of women would allow a larger
interval of screening up to 8 years in this population.
In conclusion, our experience confirms the high NPV of 99.9%
for the development of an HSIL in women with normal smears and
a negative HR-HPV test with the HC-II assay. If we compare
these results with the NPV of a normal smear alone on the same
period of follow-up, there is a significant difference in the
number of HSIL and carcinoma detected (five vs in the double-
negative women vs 34 for the total population). Our use of HPV
testing in primary screening and our protocol of follow-up clearly
explains the high number of HSIL discovered in women with
initial normal smears in the period between 12 and 72 months.
However, if we take into account the additional 32 HSIL (24 HSIL
in women 429 years) discovered before 12 months of follow-up
on a cohort of 5592 women, according to our protocol, the NPV
dramatically decreases to 98.7%. The Kaplan–Meier curves
comparing the occurrence of HSIL and carcinoma in women
with normal smears positive for HPV testing and women with a
negative HPV test clearly confirm these results. Thus, the use of
HPV testing combined with cytology significantly reduces the
limitations of cytology alone. There is always a limited false-
negative fraction represented by the five lesions detected in our
series. This fraction could be reduced and eventually abolished if
we consider a second negative HR-HPV test 1–2 years after the
initial test, which gives an NPV of 100% in our experience, but
this policy will generate a higher cost. In any case, all these
women could be safely screened at longer intervals between 3 and
5 years. This policy will offset the increased costs induced by an
additional HR-HPV testing in primary screening.
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